Heron Therapeutics Profit Margin

Heron Therapeutics (HRTX) currently reports a profit margin of -22.52% as of June 2026. That compares with -0.58% in the prior-year period — down 3750.2% year over year. That is below the Healthcare sector average of 14.41%. Use the charts on this page to explore Heron Therapeutics's profit margin history and peer comparisons.

Heron Therapeutics's profit margin decreased from -0.58% to -22.52% — a 3750.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Heron Therapeutics's profit margin of -22.52% is lower than the Healthcare sector average of 14.41%. That is roughly 256.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Heron Therapeutics's current -22.52% should be judged against Healthcare norms (sector average: 14.41%) and against HRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -22.52%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.41%. From there, open related valuation or income-statement pages for Heron Therapeutics, and consider following HRTX for alerts when major investors trade the stock.